Markets

Company News For Jun 5, 2018

  • Genomic Health, Inc's GHDX shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25
  • Shares of Bayer Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto after it finishes the $63 billion acquisition of the U.S. seed maker
  • Nektar Therapeutics' NKTR shared plummeted 41.8% after mixed results came in from studies combining Nektar's experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy
  • Shares of Deciphera Pharmaceuticals, Inc. DCPH rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Genomic Health, Inc. (GHDX): Free Stock Analysis Report

Nektar Therapeutics (NKTR): Free Stock Analysis Report

Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

DCPH NKTR

Other Topics

Investing Stocks

Latest Markets Videos